Affinage

Showing UBE2L3 — UBCH7 is a alias.

UBE2L3

Ubiquitin-conjugating enzyme E2 L3 · UniProt P68036

Length
154 aa
Mass
17.9 kDa
Annotated
2026-06-10
60 papers in source corpus 29 papers cited in narrative 28 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

UBE2L3 (UbcH7) is an E2 ubiquitin-conjugating enzyme whose catalytic specificity is defined by an inability to react with free lysine independently of an E3, restricting it to E3 ligases that employ an obligate thioester-linked ubiquitin intermediate (PMID:21532592). Consistent with this, it functions efficiently with HECT-domain E3 ligases, originally established through its interaction with E6-AP and its ability to drive E6-AP-dependent ubiquitination in vitro (PMID:8576257), and it partitions the HECT family by E2 preference, supporting thioester adduct formation on the HECT domain (PMID:9575161). Structural work on the E6AP HECT domain bound to UbcH7 defined the E2-E3 interface and showed how ubiquitin transits from E2 to E3 via a thioester relay (PMID:10558980), while the c-Cbl RING–UbcH7 structure revealed that RING domains recruit UbcH7 through a conserved E2 surface used by HECT E3s as well, positioning substrate and E2 for transfer (PMID:10966114, PMID:10531381). UBE2L3 is also the cognate E2 for RING-between-RING (RBR) E3 ligases—parkin, HHARI, and Triad1—which behave as RING/HECT hybrids: UbcH7 is engaged via a RING domain but ubiquitin passes through a conserved RING2 catalytic cysteine (PMID:21532592, PMID:19340006), with the RBR RING1 acting as a steric wedge that holds the E2~Ub conjugate in an open conformation to favor transfer to the E3 active site (PMID:28552575, PMID:30446597). Through these partnerships UBE2L3 ubiquitinates a broad substrate range, including EGFR via c-Cbl (PMID:10531381), 53BP1 to control DNA double-strand break repair pathway choice (PMID:25422456), mitochondrial proteins during Parkin-mediated mitophagy (PMID:24906799), and pro-IL-1β, which it targets with destabilizing K27/K29/K33 chains through the HECT E3s TRIP12 and AREL1 to limit mature IL-1β output and inflammation (PMID:37474493). It can also catalyze proteolytically incompetent heterotypic chains that stabilize substrates such as p27Kip1 (PMID:30113882, PMID:38301893). UBE2L3 is the preferred E2 for the LUBAC complex (HOIP/HOIL-1), driving linear-ubiquitin-dependent NF-κB activation in immune cells, including downstream of TLR7 in autoreactive B cells (PMID:25640675, PMID:26312912, PMID:37001433).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1996 High

    Establishing that UbcH7 is a functional E2 for HECT-type E3 ligases answered the basic question of which ligase class it serves.

    Evidence biochemical interaction and in vitro ubiquitination reconstitution with E6-AP

    PMID:8576257

    Open questions at the time
    • Did not define structural basis of E2-E3 recognition
    • Substrate range beyond the reconstituted system unknown
  2. 1998 High

    Showing that multiple HECT proteins form ubiquitin thioesters preferentially with UbcH7 or UbcH5 defined an E2-specificity logic within the HECT family.

    Evidence in vitro thioester formation and E2 specificity assays with domain dissection

    PMID:9575161

    Open questions at the time
    • Determinants of UbcH7 vs UbcH5 selection not resolved at residue level
    • In vivo relevance per HECT E3 untested
  3. 1999 High

    Crystallography of the E6AP HECT domain with UbcH7 and the c-Cbl RING with UbcH7 revealed that both ligase classes engage a shared E2 surface and defined the thioester transfer geometry, unifying RING and HECT mechanisms around UbcH7.

    Evidence X-ray crystallography with active-site mutagenesis; yeast two-hybrid and in vivo EGFR ubiquitination

    PMID:10531381 PMID:10558980 PMID:10966114

    Open questions at the time
    • Did not address why UbcH7 fails with most RING E3s in cells
    • Substrate channeling dynamics not captured
  4. 1999 Medium

    Identifying UbcH7 binding to RING/IBR proteins HHARI and H7-AP1, and later their perinuclear co-localization, extended its partnerships beyond classic HECT and RING ligases.

    Evidence yeast two-hybrid, in vitro binding, co-IP, co-localization, and interface mutagenesis

    PMID:10521492 PMID:11278816

    Open questions at the time
    • No functional ubiquitination reconstitution in early work
    • Physiological substrates of HHARI/UbcH7 unidentified
  5. 2004 Medium

    Functional links to HPV E7 turnover and to steroid-receptor coactivation broadened UbcH7's cellular roles beyond a generic conjugating enzyme.

    Evidence in vitro ubiquitination, Skp2-/- MEFs, reporter assays, ChIP, and co-IP

    PMID:15113913 PMID:15367689

    Open questions at the time
    • Direct E3 for E7 in vivo not fully resolved
    • Mechanism coupling conjugation activity to transcriptional coactivation unclear
  6. 2006 Medium

    Demonstrating that catalytically inactive UbcH7 (C89S) cannot drive ligand-dependent GR downregulation tied receptor turnover directly to UbcH7's conjugating activity.

    Evidence co-IP, reporter assay, dominant-negative mutagenesis, proteasome inhibitor rescue

    PMID:17003263

    Open questions at the time
    • Cognate E3 for GR not defined
    • Single-lab observation
  7. 2011 High

    Discovering that UbcH7 lacks intrinsic lysine reactivity but functions with RBR E3s via an obligate thioester intermediate explained its E3-class restriction and defined RBR ligases as RING/HECT hybrids.

    Evidence in vitro lysine reactivity and ubiquitination assays with RBR catalytic cysteine mutagenesis

    PMID:21532592

    Open questions at the time
    • Conformational basis of open vs closed E2~Ub not yet structurally resolved
    • Range of RBR substrates not enumerated
  8. 2014 Medium

    Cellular studies placed UbcH7 in DNA repair pathway choice, mitophagy, and ion channel regulation, showing the same E2 acts across distinct cellular processes through different E3/adaptor partners.

    Evidence shRNA/siRNA knockdown with DSB repair reporters; mitophagy and ubiquitination assays; yeast two-hybrid, co-IP, and patch-clamp

    PMID:24566975 PMID:24906799 PMID:25422456

    Open questions at the time
    • E3 ligase identity not pinned down in each context
    • Substrate ubiquitin chain topology mostly uncharacterized
  9. 2015 High

    Identifying UBE2L3 as the preferred E2 for LUBAC and the Ndfip1-Itch axis established its role in NF-κB-driven and inflammatory signaling.

    Evidence NF-κB reporter, dominant-negative C86S, siRNA, primary-cell imaging; co-IP, in vitro ubiquitination, Ndfip1-/- and Itch-/- mice

    PMID:25632008 PMID:25640675 PMID:26312912

    Open questions at the time
    • Mechanism linking UBE2L3 expression level to autoimmune susceptibility not fully resolved
    • Quantitative contribution relative to other LUBAC E2s unclear
  10. 2018 High

    Structural and biophysical analyses of HHARI and parkin showed how RBR RING1 enforces an open E2~Ub conformation and how parkin phosphorylation plus UbcH7~Ub recruitment synergistically activate the catalytic cysteine, defining the activation mechanism.

    Evidence X-ray crystallography, NMR, HDX-MS, and in vitro ubiquitination

    PMID:28552575 PMID:30446597

    Open questions at the time
    • Full catalytic cycle dynamics not captured in one structure
    • Generalizability across all RBR family members untested
  11. 2018 Medium

    Showing UBE2L3 builds proteolytically incompetent heterotypic chains on p27Kip1 demonstrated that it can stabilize rather than destabilize substrates depending on chain topology.

    Evidence overexpression/knockdown, cell cycle analysis, in vitro ubiquitination with chain characterization

    PMID:30113882

    Open questions at the time
    • E3 ligase responsible not identified in this study
    • Physiological prevalence of these chains unknown
  12. 2023 High

    Conditional Ube2l3 knockout in mice defined an in vivo anti-inflammatory function via TRIP12/AREL1-dependent K27/K29/K33 ubiquitylation of pro-IL-1β and connected UBE2L3-LUBAC to TLR7-driven B-cell autoimmunity.

    Evidence Ube2l3 conditional KO mouse, RNAi screen, ubiquitination and inflammasome assays; siRNA, NF-κB reporter, B-cell differentiation, DMF inhibition

    PMID:37001433 PMID:37474493

    Open questions at the time
    • How chain topology dictates pro-IL-1β proteasomal disposal mechanistically unclear
    • DMF target selectivity for UBE2L3 in vivo not fully delineated
  13. 2024 Medium

    Partner-specific studies identified SMURF1 cooperation in K29-linked p27 stabilization at the migrating cell edge and MARCHF8-mediated degradation of UBE2L3 controlling HPV E7 levels, refining its substrate and regulatory networks.

    Evidence in vitro ubiquitination with chain mutants, co-localization, migration assays; co-IP, ubiquitination, and xenograft rescue

    PMID:38226814 PMID:38301893

    Open questions at the time
    • Reciprocal validation across systems limited
    • In vivo significance of the SMURF1/p27 axis untested
  14. 2026 Low

    Reports linking UBE2L3 to MLKL-dependent necroptosis and to SMURF2-mediated TSC2/mTOR/autophagy control in cancer extend its proposed roles but rest on limited mechanistic depth.

    Evidence co-IP, ubiquitination, knockdown, xenografts; in vivo CRISPR screen and autophagy assays

    PMID:39988669 PMID:41943836

    Open questions at the time
    • Single-lab co-IP/knockdown without reciprocal validation
    • Direct ubiquitination of stated substrates and chain topology not firmly established
    • Pathway placement partially inferred

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how UBE2L3 expression level and chain-type output are selected across its many E3 partners to produce opposite (stabilizing vs degradative) outcomes on different substrates in vivo.
  • No unifying model linking E3 partner choice to chain topology
  • Quantitative control of substrate fate by UBE2L3 abundance not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 4 GO:0016740 transferase activity 3
Localization
GO:0005886 plasma membrane 2 GO:0005829 cytosol 1
Pathway
R-HSA-392499 Metabolism of proteins 4 R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3 R-HSA-9612973 Autophagy 2 R-HSA-73894 DNA Repair 1
Partners
AREL1CBLE6-APHHARIITCHPARK2SMURF1TRIP12
Complex memberships
LUBAC

Evidence

Reading pass · 28 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 Crystal structure of the E6AP HECT domain bound to UbcH7 revealed the determinants of E2-E3 specificity and showed how ubiquitin is transferred from the E2 to the E3 via a thioester intermediate; conserved residues in the HECT catalytic cleft are required for ubiquitin-thioester bond formation. X-ray crystallography; active-site mutagenesis Science High 10558980
2000 Crystal structure of c-Cbl bound to UbcH7 (and a kinase peptide) showed that the RING domain recruits UbcH7 via a conserved E2 surface motif also used by HECT E3s, and revealed a rigid coupling between substrate-binding and E2-binding domains with a conserved channel leading to the E2 active site, suggesting RING E3s act as scaffolds positioning substrate and E2 for ubiquitin transfer. X-ray crystallography Cell High 10966114
1999 The c-Cbl RING finger domain directly interacts with UbcH7; this interaction is disrupted by the oncogenic 70Z-Cbl deletion. c-Cbl and UbcH7 synergistically promote ligand-induced ubiquitination of the EGFR in vitro and in vivo, while 70Z-Cbl suppresses this ubiquitination. Yeast two-hybrid; in vitro binding assay; in vivo ubiquitination assay Journal of Biological Chemistry High 10531381
1996 UbcH7 (UBE2L3) was cloned and shown to interact with the HECT E3 ligase E6-AP and to efficiently substitute for UbcH5 in E6-AP-dependent ubiquitination in vitro, establishing UbcH7 as a functional E2 for HECT-type E3s. Biochemical interaction assay; in vitro ubiquitination reconstitution Journal of Biological Chemistry High 8576257
1998 Multiple human HECT-domain proteins form thioester complexes with ubiquitin using UbcH7 or UbcH5 as their preferred E2, dividing the HECT family into at least two classes based on E2 specificity; the HECT domain alone is necessary and sufficient for ubiquitin thioester adduct formation. In vitro ubiquitin thioester formation assay; E2 specificity binding assays Journal of Biological Chemistry High 9575161
2011 UbcH7 lacks intrinsic E3-independent reactivity with lysine (unlike many other E2s), explaining its preference for HECT-type E3s. UbcH7 is active with RBR family E3s (parkin, HHARI), which function as RING/HECT hybrids: they bind UbcH7 via a RING domain but transfer ubiquitin through an obligate thioester-linked intermediate requiring a conserved cysteine in RING2. In vitro lysine reactivity assay; in vitro ubiquitination assay; mutagenesis of RBR catalytic cysteine Nature High 21532592
1999 UbcH7 interacts with HHARI and H7-AP1 via their RING finger and IBR domains in vitro. This interaction is specific: both proteins bind UbcH8 but not UbcH5 or UbcH1, linking a subset of RING/IBR proteins to the ubiquitin pathway via UbcH7. Yeast two-hybrid; in vitro binding assay Journal of Biological Chemistry Medium 10521492
2001 HHARI interacts and co-localizes with UbcH7 in the perinuclear region of mammalian cells. A minimal interaction region (residues 186-254 of HHARI) was defined; specific residues in the RING1 domain and the distance between RING1 and IBR are critical. Mutation of RING1 from RING-HC to RING-H2 type abolishes binding to UbcH7. Co-immunoprecipitation; co-localization (immunofluorescence); deletion/point mutagenesis Journal of Biological Chemistry Medium 11278816
2004 UbcH7 is specifically involved in ubiquitination of HPV E7; E7 interacts with the SCF complex containing Cul1 and Skp2 and can be ubiquitinated by the Cul1-containing ubiquitin ligase in vitro. E7 half-life is significantly longer in Skp2-/- MEFs than wild-type. In vitro ubiquitination assay; co-immunoprecipitation; Skp2-/- MEF genetic analysis Journal of Virology Medium 15113913
2004 UBCH7 acts as a transcriptional coactivator for steroid hormone receptors (PR, GR, AR, RAR) in a hormone-dependent manner; its ubiquitin conjugation activity is required for this coactivation function. UBCH7 is recruited to estrogen receptor- and PR-responsive promoters in a hormone-dependent manner and interacts with SRC-1. Transient transfection reporter assay; siRNA depletion; chromatin immunoprecipitation (ChIP); co-immunoprecipitation Molecular and Cellular Biology Medium 15367689
2006 UbcH7 physically interacts with the glucocorticoid receptor (GR) and reduces GR-dependent gene expression when overexpressed; a dominant-negative UbcH7 (C89S, catalytically inactive) fails to repress GR transactivation and abolishes ligand-dependent GR protein downregulation, establishing that UbcH7 regulates GR turnover via its ubiquitin-conjugating activity. Co-immunoprecipitation; transient transfection reporter assay; dominant-negative mutagenesis; proteasome inhibitor rescue Journal of Endocrinology Medium 17003263
2014 UbcH7 regulates both steady-state and replicative stress-induced ubiquitination and proteasomal degradation of 53BP1. Depletion of UbcH7 stabilizes 53BP1, inhibits DSB end resection, shifts repair from homologous recombination to NHEJ, and sensitizes cells to DNA damage. shRNA library screen; siRNA knockdown; ubiquitination assay; DSB repair assay (HR/NHEJ reporters) PNAS Medium 25422456
2014 UBE2L3, UBE2N, and UBE2D2/3 synergistically contribute to Parkin-mediated mitophagy; UBE2L3 knockdown reduces autophagic clearance of depolarized mitochondria and reduces ubiquitination of mitochondrial substrates (mitofusins, TOM20, TOM70, VDAC1) without interfering with PINK1 stabilization or Parkin translocation. siRNA knockdown; mitophagy assay; ubiquitination assay; flow cytometry Journal of Cell Science Medium 24906799
2015 UBE2L3 is the preferred E2 conjugating enzyme for the LUBAC complex (HOIL-1/HOIP) in vivo and is essential for LUBAC-mediated NF-κB activation. Dominant-negative UBE2L3 (C86S) or UBE2L3 silencing abolishes LUBAC-induced NF-κB upregulation. HEK293-NF-κB reporter assay; dominant-negative mutagenesis; siRNA knockdown; imaging flow cytometry for NF-κB translocation in primary cells American Journal of Human Genetics / Lancet High 25640675 26312912
2005 HIV Nef mediates exclusion of UbcH7 from lipid rafts via formation of a p85Cool-1/betaPix–c-Cbl–Cdc42 ternary complex that displaces UbcH7 from rafts, preventing ubiquitination of activated Vav and thereby increasing T cell signaling. Lipid raft fractionation; co-immunoprecipitation; siRNA knockdown of p85Cool-1/betaPix Immunity Medium 16356860
2009 The RBR E3 ligase Triad1 interacts with UbcH7 through its first RING domain and with Ubc13 through its second RING domain; both interactions and full-length Triad1 are required for inhibition of myeloid colony formation, demonstrating that UbcH7-dependent ubiquitination through Triad1 is biologically essential for myelopoiesis. In vitro binding assay; domain mutagenesis; myeloid clonogenic assay Leukemia Medium 19340006
2009 UbcH7 overexpression delays S phase entry while its depletion lengthens S phase and decreases cell proliferation; UbcH7 depletion increases Chk1 levels and decreases phosphorylated PTEN, indicating UbcH7 regulates S phase length through a PTEN/Akt/Chk1 pathway. Overexpression; siRNA knockdown; cell cycle analysis (flow cytometry); Western blot Cell Division Low 19664228
2015 Ndfip1 acts as an adaptor that recruits UbcH7 to the HECT E3 Itch: Ndfip1 N-terminus binds UbcH7 while its PY motif binds Itch, enhancing Itch ligase activity and Itch-mediated K63 ubiquitination of Tak1, limiting airway inflammation. Co-immunoprecipitation; in vitro ubiquitination assay; Ndfip1-/- mouse model; Itch-/- mouse model; siRNA/mutagenesis rescue Journal of Immunology Medium 25632008
2017 HHARI RING1 contains a Zn2+-loop II extension not present in canonical RING E3s that acts as a steric wedge to prevent closed E2~Ub conformation, structurally explaining how RBR RING1 domains promote open E2~Ub conformation to favor Ub transfer to the E3 active site rather than direct transfer to substrate. X-ray crystallography; structural comparison Structure High 28552575
2018 UbcH7~Ub conjugate binds to the RING1/IBR interface of parkin in the open (not closed) E2~Ub state; NMR and mass spectrometry show that parkin phosphorylation and UbcH7~Ub recruitment act synergistically to rearrange the RING0/RING2 interface and alter reactivity of the RING2 catalytic cysteine (Rcat), driving parkin ubiquitination activity. NMR chemical shift perturbation; hydrogen-deuterium exchange mass spectrometry; in vitro ubiquitination assay EMBO Journal High 30446597
2018 UBCH7/UBE2L3 overexpression stabilizes p27Kip1 and delays the G1-to-S cell cycle transition; depletion of UBE2L3 increases p27Kip1 turnover. The stabilization mechanism involves UBE2L3-catalyzed conjugation of heterotypic ubiquitin chains on p27Kip1 that are proteolytically incompetent. Overexpression; siRNA knockdown; cell cycle analysis; in vitro ubiquitination assay with heterotypic chain characterization FASEB Journal Medium 30113882
2014 MAP1B light chain 1 (LC1) interacts with UBE2L3 (via yeast two-hybrid and co-IP), and the LC1/UBE2L3 complex co-immunoprecipitates with CaV2.2 N-type Ca2+ channels, promoting their ubiquitination and proteasomal degradation, thereby reducing channel surface expression and current amplitude. Yeast two-hybrid; co-immunoprecipitation; patch-clamp electrophysiology; proteasome inhibitor rescue Pflügers Archiv Medium 24566975
2023 UBE2L3 promotes pro-IL-1β ubiquitylation and proteasomal disposal; deletion of Ube2l3 in mice reduces pro-IL-1β turnover in macrophages, leading to excessive mature IL-1β production and neutrophilic inflammation. An RNAi screen identified HECT E3 ligases TRIP12 and AREL1 as the E3 partners adding destabilizing K27-, K29-, and K33-linked poly-ubiquitin chains on pro-IL-1β. Ube2l3 conditional knockout mouse; RNAi screen; ubiquitination assays; inflammasome activation assays Nature Communications High 37474493
2023 UBE2L3 is critical for NF-κB activation downstream of TLR7 stimulation via interaction with LUBAC. Dimethyl fumarate (DMF), which directly inhibits UBE2L3, blocks TLR7-induced NF-κB activation, differentiation of memory B cells and plasmablasts, and autoantibody secretion in SLE B cells. siRNA knockdown; NF-κB reporter assay; flow cytometry for B cell differentiation; ELISA for autoantibodies Journal of Autoimmunity Medium 37001433
2024 MARCHF8 E3 ubiquitin ligase binds to and ubiquitinates both CUL1 and UBE2L3, leading to their degradation and thereby preventing ubiquitination and degradation of HPV16 E7; overexpression of CUL1 or UBE2L3 restores E7 degradation and suppresses tumor growth in vivo. Co-immunoprecipitation; ubiquitination assay; siRNA knockdown; in vivo tumor xenograft Journal of Virology Medium 38226814
2024 SMURF1 (but not SMURF2) works with UbcH7 to ubiquitinate p27 with K29-linked chains in vitro, stabilizing p27. SMURF1, UbcH7, and p27 co-localize at the leading edge of migrating cells, and knockdown of SMURF1 or UbcH7 reduces cell migration. In vitro ubiquitination screen; in vitro ubiquitination with K29R/K29O mutant ubiquitin; siRNA knockdown; co-localization by fluorescence microscopy; cell migration assay Journal of Biological Chemistry Medium 38301893
2025 UBE2L3 specifically binds MLKL via co-immunoprecipitation and promotes its ubiquitination; overexpression of UBE2L3 reduces MLKL expression, while UBE2L3 knockdown increases MLKL phosphorylation and promotes necroptosis in osteosarcoma cells and in vivo. Co-immunoprecipitation; ubiquitination assay; siRNA knockdown; in vivo tumor xenograft; immunohistochemistry World Journal of Surgical Oncology Low 39988669
2026 In vivo CRISPR screen identified UBE2L3 as a regulator of autophagy in TNBC; mechanistically, UBE2L3 interacts with E3 ligase SMURF2 to ubiquitinate and degrade TSC2, thereby activating mTOR and suppressing autophagy. In vivo CRISPR/Cas9 library screen; co-immunoprecipitation; ubiquitination assay; autophagy assays International Journal of Biological Sciences Low 41943836

Source papers

Stage 0 corpus · 60 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2000 Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 722 10966114
1999 Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science (New York, N.Y.) 473 10558980
2011 UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids. Nature 461 21532592
1999 Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. The Journal of biological chemistry 278 10531381
1998 Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7. The Journal of biological chemistry 143 9575161
1996 Cloning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterization of their interaction with E6-AP and RSP5. The Journal of biological chemistry 137 8576257
1999 The ubiquitin-conjugating enzymes UbcH7 and UbcH8 interact with RING finger/IBR motif-containing domains of HHARI and H7-AP1. The Journal of biological chemistry 101 10521492
2014 The ubiquitin-conjugating enzymes UBE2N, UBE2L3 and UBE2D2/3 are essential for Parkin-dependent mitophagy. Journal of cell science 96 24906799
2015 UBE2L3 polymorphism amplifies NF-κB activation and promotes plasma cell development, linking linear ubiquitination to multiple autoimmune diseases. American journal of human genetics 84 25640675
2004 The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. Journal of virology 80 15113913
2004 The ubiquitin-conjugating enzyme UBCH7 acts as a coactivator for steroid hormone receptors. Molecular and cellular biology 74 15367689
2001 Features of the parkin/ariadne-like ubiquitin ligase, HHARI, that regulate its interaction with the ubiquitin-conjugating enzyme, Ubch7. The Journal of biological chemistry 69 11278816
2016 Mechanism and disease association of E2-conjugating enzymes: lessons from UBE2T and UBE2L3. The Biochemical journal 62 27729585
2012 A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. Genes and immunity 50 22476155
2017 Structural Studies of HHARI/UbcH7∼Ub Reveal Unique E2∼Ub Conformational Restriction by RBR RING1. Structure (London, England : 1993) 48 28552575
2018 Synergistic recruitment of UbcH7~Ub and phosphorylated Ubl domain triggers parkin activation. The EMBO journal 44 30446597
2014 UbcH7 regulates 53BP1 stability and DSB repair. Proceedings of the National Academy of Sciences of the United States of America 40 25422456
2005 Nef-mediated lipid raft exclusion of UbcH7 inhibits Cbl activity in T cells to positively regulate signaling. Immunity 33 16356860
2013 Variants in TNFSF4, TNFAIP3, TNIP1, BLK, SLC15A4 and UBE2L3 interact to confer risk of systemic lupus erythematosus in Chinese population. Rheumatology international 32 24091983
2022 Mechanism and Disease Association With a Ubiquitin Conjugating E2 Enzyme: UBE2L3. Frontiers in immunology 31 35265070
2009 The ubiquitin ligase Triad1 inhibits myelopoiesis through UbcH7 and Ubc13 interacting domains. Leukemia 29 19340006
2011 The autoimmune disease risk allele of UBE2L3 in African American patients with systemic lupus erythematosus: a recessive effect upon subphenotypes. The Journal of rheumatology 24 22045845
2014 CaV2.2 channel cell surface expression is regulated by the light chain 1 (LC1) of the microtubule-associated protein B (MAP1B) via UBE2L3-mediated ubiquitination and degradation. Pflugers Archiv : European journal of physiology 23 24566975
2006 UbcH7 interacts with the glucocorticoid receptor and mediates receptor autoregulation. The Journal of endocrinology 22 17003263
2023 IL-1β turnover by the UBE2L3 ubiquitin conjugating enzyme and HECT E3 ligases limits inflammation. Nature communications 21 37474493
2020 Synergistic activation of NF-κB by TNFAIP3 (A20) reduction and UBE2L3 (UBCH7) augment that synergistically elevate lupus risk. Arthritis research & therapy 21 32334614
1998 Fine-mapping, genomic organization, and transcript analysis of the human ubiquitin-conjugating enzyme gene UBE2L3. Genomics 18 9693040
1996 Characterization of a human ubiquitin-conjugating enzyme gene UBE2L3. Mammalian genome : official journal of the International Mammalian Genome Society 18 8672131
2018 Stabilization of p27Kip1/CDKN1B by UBCH7/UBE2L3 catalyzed ubiquitinylation: a new paradigm in cell-cycle control. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 16 30113882
2018 UBE2L3, a susceptibility gene that plays oncogenic role in hepatitis B-related hepatocellular carcinoma. Journal of viral hepatitis 15 29969176
2015 Effect of UBE2L3 genotype on regulation of the linear ubiquitin chain assembly complex in systemic lupus erythematosus. Lancet (London, England) 15 26312912
2023 UBE2L3 regulates TLR7-induced B cell autoreactivity in Systemic Lupus Erythematosus. Journal of autoimmunity 14 37001433
2014 The MAP1B-LC1/UBE2L3 complex catalyzes degradation of cell surface CaV2.2 channels. Channels (Austin, Tex.) 14 25483588
2021 Long non-coding RNA LINC01116 acts as an oncogene in prostate cancer cells through regulation of miR-744-5p/UBE2L3 axis. Cancer cell international 13 33726770
2020 HP1γ Sensitizes Cervical Cancer Cells to Cisplatin through the Suppression of UBE2L3. International journal of molecular sciences 13 32825184
2015 Ndfip1 regulates itch ligase activity and airway inflammation via UbcH7. Journal of immunology (Baltimore, Md. : 1950) 13 25632008
2009 Ubiquitin control of S phase: a new role for the ubiquitin conjugating enzyme, UbcH7. Cell division 13 19664228
2022 Indole-3-Carbinol, a Phytochemical Aryl Hydrocarbon Receptor-Ligand, Induces the mRNA Overexpression of UBE2L3 and Cell Proliferation Arrest. Current issues in molecular biology 12 35678668
2017 TCDD induces UbcH7 expression and synphilin-1 protein degradation in the mouse ventral midbrain. Journal of biochemical and molecular toxicology 12 28621812
2008 Modelling and molecular dynamics of the interaction between the E3 ubiquitin ligase Itch and the E2 UbcH7. Biochemical pharmacology 12 18805400
2024 The membrane-associated ubiquitin ligase MARCHF8 stabilizes the human papillomavirus oncoprotein E7 by degrading CUL1 and UBE2L3 in head and neck cancer. Journal of virology 11 38226814
2022 UBE2L3 Reduces TRIM21 Expression and IL-1β Secretion in Epidermal Keratinocytes and Improves Psoriasis-Like Skin. The Journal of investigative dermatology 11 36502938
2016 The haplotype of UBE2L3 gene is associated with Hashimoto's thyroiditis in a Chinese Han population. BMC endocrine disorders 10 27094594
2022 UBE2L3 promotes squamous cell carcinoma progression in the oral cavity and hypopharynx via activating the NF-κB signaling by increasing IκBα degradation. Cell biology international 8 35128752
2022 UBE2L3 promotes lung adenocarcinoma invasion and metastasis through the GSK-3β/Snail signaling pathway. American journal of translational research 8 35958458
2007 1H, 13C and 15N resonance assignments for the human E2 conjugating enzyme, UbcH7. Biomolecular NMR assignments 7 19636915
2021 Variants on the UBE2L3/YDJC Autoimmune Disease Risk Haplotype Increase UBE2L3 Expression by Modulating CCCTC-Binding Factor and YY1 Binding. Arthritis & rheumatology (Hoboken, N.J.) 6 34279042
2000 Promoter analysis of the human ubiquitin-conjugating enzyme gene family UBE2L1-4, including UBE2L3 which encodes UbcH7. Biochimica et biophysica acta 5 10760570
2024 The E3 ligase SMURF1 stabilizes p27 via UbcH7 catalyzed K29-linked ubiquitin chains to promote cell migration SMURF1-UbcH7 K29 ubiquitination of p27 and cell migration. The Journal of biological chemistry 4 38301893
2025 UBE2L3 Suppresses Oxidative Stress-regulated Necroptosis to Accelerate Osteosarcoma Progression. Recent patents on anti-cancer drug discovery 3 38385491
2025 Single cell transcriptomics of human psoriasis and epidermal specific Ube2l3 deficient mice highlight CXCL16/CXCR6 involvement in psoriasis development. Nature communications 3 41083457
2024 UBE2L3 promotes benzene-induced hematotoxicity via autophagy-dependent ferroptosis. Ecotoxicology and environmental safety 3 39059346
2019 1H, 13C, 15N backbone and side-chain resonance assignment of the native form of UbcH7 (UBE2L3) through solution NMR spectroscopy. Biomolecular NMR assignments 3 31792831
2024 Combined Genetic Association and Differed Expression Analysis of UBE2L3 Uncovers a Genetic Regulatory Role of (Immuno)proteasome in IgA Nephropathy. Kidney diseases (Basel, Switzerland) 2 38835407
2012 [Screening and identification of anoikis-resistant gene UBCH7 in esophageal cancer cells]. Yi chuan = Hereditas 2 22382060
2025 Interfering with UBE2L3 expression targets regulation of MLKL to promote necroptosis inhibition of growth in osteosarcoma. World journal of surgical oncology 1 39988669
2026 In vivo CRISPR/Cas9 Screening Reveals that UBE2L3 Modulates Autophagic Flux through TSC2 Ubiquitination and Potentiates PD-1 Blockade in Triple-Negative Breast Cancer. International journal of biological sciences 0 41943836
2024 UBE2L3 expression in human gastric cancer and its clinical significance. Journal of cancer research and clinical oncology 0 38656363
2023 The membrane-associated ubiquitin ligase MARCHF8 stabilizes the human papillomavirus oncoprotein E7 by degrading CUL1 and UBE2L3 in head and neck cancer. bioRxiv : the preprint server for biology 0 37961092
2017 [Predictive value of single nucleotide polymorphisms of HLA-C and UBE2L3 in evaluating the effect of telbivudine antiviral therapy during pregnancy]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 0 29056010

Missed literature

Know a paper Affinage missed for UBE2L3? Flag it for the maintainers and the community.

No submissions yet.